Methods: Eligible patients were allowed to have two prior systemic therapies. The primary endpoint was 16 weeks progression-free survival PFS , and secondary endpoints included response, stable disease, and overall survival. Patients with BTC and HCC were accrued and assessed in separate strata for the efficacy endpoints, but for the two-stage initial design of the study, combined PFS was considered.
No objective responses were seen. Median overall survival was 5. About Forte Research Systems, Inc. Now, its proven electronic data capture platform is available as a stand-alone hosted solution for academic researchers, Overture EDC. Forte is also host to the Clinical Research Blog and other resources for individuals interested in excellence in clinical research operations. The HOG is committed to improving therapy for cancer patients through clinical research throughout its network.
HOG celebrated its 25th anniversary with a gala on April Since its inception, the group has helped enroll 3, patients in more than clinical trials. Complementing its core mission, HOG also administers research beyond the state's boundaries.
That it brings cancer research close to home for patients makes HOG unique among other clinical research organizations. HOG trials have helped alter the standards of cancer care. HOG doctors have assisted in evaluating complex treatment protocols.
HOG clinical trial research has shown that sometimes, complex protocols are no better than simpler therapies -- and may even be worse, since cancer therapies often involve the administration of mildly toxic chemicals.
0コメント